World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0009701299
Reproduction Date:

Title: Stamulumab  
Author: World Heritage Encyclopedia
Language: English
Subject: Muscular dystrophy, Facioscapulohumeral muscular dystrophy, Wyeth, Rinucumab, Evinacumab
Publisher: World Heritage Encyclopedia


Monoclonal antibody
Type Whole antibody
Source Human
Target myostatin
Clinical data
Routes of
injection only
CAS Registry Number  N
ATC code None
Chemical data
Formula C6330H9748N1672O1668S48
Molecular mass 137.5 kDa

Stamulumab (MYO-029[1]) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy (MD). Stamulumab was formulated and tested by Wyeth in Collegeville, Pennsylvania.[2] Myostatin is a protein that inhibits the growth of muscle tissue, stamulumab is a recombinant human antibody designed to bind to and inhibit the activity of myostatin.[3]

Stamulumab is a G1 immunoglobulin antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin on muscle tissue. Research completed in 2002 found that Stamulumab might one day prove to be an effective treatment for Duchenne muscular dystrophy[4]

Phase 1 and 2 trials

Wyeth undertook a Phase 1 and 2 clinical trial in 2005 and 2006 of stamulumab. The multiple ascending dose trial (36 patients per cohort) contained some measures of efficacy. The trial's participants included people afflicted with Facioscapulohumeral muscular dystrophy, Becker's muscular dystrophy, and Limb-girdle muscular dystrophy. Through 2007 Wyeth had been analyzing the results but the hoped-for news and/or a publication in 2007 did not occur.[2][5][6] In January 24, 2008, Wyeth announced that the study had been accepted by a peer-reviewed journal and publication was expected "in the next few months".[7] The publication appeared in Annals of Neurology in May 2008. [8]

On 11 March 2008 it was announced that Wyeth would not develop the drug further for MD, but would continue to explore myostatin inhibition along with other strategies.[9]

See also

  • ACVR2B represents an alternative approach to inhibiting myostatin. Not belonging to the antibody class of molecules, the ACVR2B protein drug is rather mimicking myostatin's endogenous binding partner, therefore competing for its binding affinity. [10]


  1. ^ Wyeth Product Pipeline, Wyeth, Website accessed April 22, 2007
  2. ^ a b NIH's, Study Evaluating MYO-029 in Adult Muscular Dystrophy, record last updated January 24, 2007
  3. ^, Wyeth Initiates Clinical Trial with Investigational Muscular Dystrophy Therapy MYO-029, Article Date: 28 Feb 2005 - 7:00 PDT
  4. ^ Blocking Myostatin Proves Beneficial in Mice with DMD, MDA Research News, 27 November 2002
  5. ^ Wyeth Analyzing MYO-029 Results, Muscular Dystrophy Association announcement, December 4, 2006
  6. ^ FSH Watch Newsletter, pg 11, FSH Society, Summer 2007
  7. ^ Pharma Company Responds to WiSci on Muscle-Building Drug, Wired Science, Alexis Madrigal, January 24, 2008, 2008, 4:26:27 PM
  8. ^ A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy., Ann Neurol. 2008 May;63(5):561-71.
  9. ^ Wyeth Won't Develop MYO-029 for MD
  10. ^ New Myostatin Blocker Makes Mouse Muscles 60 Percent Larger, MDA Research News, January 6, 2006
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.